Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma

@article{Yoo2014PrognosticIO,
  title={Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma},
  author={C. Yoo and D. Yoon and J. Jo and Shinkyo Yoon and Shin-Ae Kim and B. Lee and J. Huh and Sang-Wook Lee and C. Suh},
  journal={Annals of Hematology},
  year={2014},
  volume={93},
  pages={995-1000}
}
Although serum beta-2 microglobulin (B2M) has been suggested as an independent prognostic factor for several lymphoproliferative diseases, it has rarely been investigated in extranodal natural killer/T cell lymphoma (ENKTL). From a prospectively collected database, 145 patients with ENKTL were identified. Among them, a total of 101 patients were included in the analysis, with exclusion of patients without baseline serum B2M level and those did not receive anticancer therapy. Serum B2M (<3.0 vs… Expand
Prognostic impact of β2-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma
TLDR
Baseline serum B2M is an independent prognostic factor in patients with non-gastric MALT lymphoma, and is significantly associated with progression-free survival and overall survival. Expand
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
TLDR
The significance of serum beta-2 microglobulin levels as an independent prognostic factor for patients with DLBCL receiving R-CHOP is confirmed and the five parameters of the International Prognostic Index were associated with worse PFS and OS. Expand
Beta‐2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B‐cell lymphoma
TLDR
A new prognostic index composed of age, performance status, stage, and B2MG could stratify the outcomes of patients with DLBCL effectively and appears to be a valuable risk model for these patients. Expand
Serum beta‐2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma
TLDR
Pretreatment serum B2M may be an independent and significant prognostic factor in patients with MCL and was significantly associated with OS in multivariate analyses adjusted for MIPi or MIPI‐b scores and rituximab. Expand
Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
TLDR
A new prognostic index model for DLBCL in the rituximab era has good discriminative power and is convenient to use and showed better discrim inative power compared with the classic IPI. Expand
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
TLDR
High NLR is an independent prognostic marker and the NABS model can be used to risk-stratify NKTL patients, a retrospective review of 178 patients with biopsy-proven NKTL finds. Expand
Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience
TLDR
It is suggested that non-nasal NKTCL is the only poor prognostic factor of OS and PFS in Peru, similar to other countries. Expand
Correlation between the clinicopathological features and prognosis in patients with extranodal natural killer/T cell lymphoma
TLDR
Granzyme B, perforin, and Bcl-2 expression and Ki-67 overexpression might be adverse prognostic factors for ENKTCL, whereas PDGFRA-positivity suggested a better disease prognosis. Expand
BETA-2 MICROGLOBULIN: A NOVEL BIO-MARKER ASSISTING IN THE DIAGNOSIS OF LYMPHOMA: A STUDY OF 669 NEWLY DIAGNOSED LYMPHOMA CASES IN THE SOUTH OF IRAQ
TLDR
The results showed an elevated level of B2MG among both Hodgkin & non-Hodgkin, adults and childhood and nodal and extranodal lymphomas, with a significant increase among non- HodGkin and extransodal type of lymphoma, a finding that may make its use as a diagnostic marker is helpful. Expand
SERUM β2 MICROGLOBULIN AND LACTATE DEHYDROGENASE 2 ISOENZYME AS MARKERS OF BONE MARROW INFILTRATION IN NON-HODGKIN LYMPHOMA -
TLDR
The levels of β2m and LD2 showed positive correlation with the extent of the disease, so it is concluded that non-invasive parameters are useful indicator of the extentof the disease. Expand
...
1
2
...

References

SHOWING 1-10 OF 29 REFERENCES
Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma
TLDR
It is suggested high serum β2-M was a novel predictor of prognosis in patients with UNKTL, and a simply and regular way might be established to identify UNK TL patients of different risks at diagnosis. Expand
Serum β2 microglobulin in malignant lymphoproliferative disorders
TLDR
Serum beta‐2‐microglobulin was measured at diagnosis in 44 patients with lymphocytic leukemias and 47 with malignant lymphomas and no significant association was found between S‐β2M level and histologic subtypes, presence of B symptoms, bone marrow involvement, and survival. Expand
Serum beta 2 microglobulin in malignant lymphoproliferative disorders.
TLDR
Serum beta-2-microglobulin was measured at diagnosis in 44 patients with lymphocytic leukemias and 47 with malignant lymphomas and no significant association was found between S-beta 2M level and histologic subtypes, presence of B symptoms, bone marrow involvement, and survival. Expand
Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study.
  • Jeeyun Lee, C. Suh, +16 authors W. Kim
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
The newly proposed model for extranodal NK/T-cell lymphoma demonstrated a more balanced distribution of patients into four groups with better prognostic discrimination as compared with the International Prognostic Index. Expand
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
TLDR
The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with a better outcome in anaplastic large-cell lymphoma, ALK positive. Expand
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
TLDR
Follicular Lymphoma International Prognostic Index 2 is a simple prognostic index based on easily available clinical data and may represent a promising new tool for the identification of patients with FL at different risk in the era of immunochemotherapy. Expand
Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
Summary. Previous reports have shown serum beta2 microglobulin (SB2M) to be a reliable marker for evaluation of presenting tumour mass, response to chemotherapy and prognosis of patients withExpand
Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia
  • R. Suzuki
  • Medicine
  • International journal of hematology
  • 2010
TLDR
The SMILE (steroid, methotrexate, ifosfamide, l-asparaginase and etoposide) regimen is one of the promising regimens for advanced or relapsed/refractory ENKL, but its myelotoxicity is strong. Expand
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.
TLDR
Data on 52 men and 15 women with well-characterized nasal NK cell lymphomas were analyzed retrospectively to define the impact of primary therapy on remission and long-term outcome and the validity of the International Prognostic Index. Expand
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
TLDR
It is concluded that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma, however, the underlying features responsible for these differences remain to be defined. Expand
...
1
2
3
...